Andra AP fonden Has $8.26 Million Holdings in Boston Scientific Corporation $BSX

Key Points

• Andra AP fonden increased its Boston Scientific stake by 13.9% in the second quarter, owning 193,622 shares valued at approximately $8.26 million. Institutional investors collectively hold 89.07% of the company.
• Analysts maintain a generally positive view, with 23 Buy, six Hold, and two Sell ratings. Boston Scientific has a consensus rating of “Moderate Buy” and an average price target of $70.27.
• The company exceeded quarterly expectations, reporting $0.86 in earnings per share and $5.44 billion in revenue, while revenue grew 7.5% year over year. CEO Michael Mahoney and director Edward Ludwig also purchased company shares recently.

Andra AP fonden increased its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 13.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 193,622 shares of the medical equipment provider's stock after buying an additional 23,694 shares during the quarter. Andra AP fonden's holdings in Boston Scientific were worth $8,264,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. BlackRock Inc. acquired a new position in Boston Scientific in the second quarter valued at about $5,534,781,000. Primecap Management Co. CA acquired a new stake in shares of Boston Scientific during the second quarter worth approximately $2,156,233,000. Norges Bank acquired a new stake in shares of Boston Scientific during the fourth quarter worth approximately $2,199,395,000. Jupiter Topco LLC bought a new position in shares of Boston Scientific in the second quarter valued at approximately $803,357,000. Finally, Bank of America Corp DE acquired a new position in shares of Boston Scientific in the 2nd quarter worth approximately $556,026,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on BSX shares. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a research report on Thursday, May 28th. Needham & Company LLC cut their price objective on Boston Scientific from $77.00 to $57.00 and set a "buy" rating for the company in a research report on Wednesday, July 8th. Argus reissued a "hold" rating on shares of Boston Scientific in a research note on Friday, July 31st. Canaccord Genuity Group decreased their target price on Boston Scientific from $70.00 to $66.00 and set a "buy" rating on the stock in a report on Thursday, July 30th. Finally, TD Cowen restated a "buy" rating on shares of Boston Scientific in a research note on Thursday, September 17th. Twenty-three equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $70.27.

Boston Scientific Stock Up 2.9%

NYSE:BSX opened at $44.99 on Wednesday. The company has a market cap of $65.21 billion, a price-to-earnings ratio of 18.22, a P/E/G ratio of 1.02 and a beta of 0.57. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The stock's fifty day moving average price is $46.93 and its two-hundred day moving average price is $53.01. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $105.65.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to analysts' expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business's revenue for the quarter was up 7.5% on a year-over-year basis. During the same period last year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts anticipate that Boston Scientific Corporation will post 3.27 EPS for the current year.

Insider Transactions at Boston Scientific

In related news, Director Edward J. Ludwig bought 5,000 shares of Boston Scientific stock in a transaction on Friday, July 31st. The shares were purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the acquisition, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael F. Mahoney bought 186,240 shares of the firm's stock in a transaction dated Monday, August 3rd. The shares were bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 194,522 shares of company stock worth $9,385,210 in the last three months. Insiders own 0.34% of the company's stock.

About Boston Scientific

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company's products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.